Edition:
India

Karyopharm Therapeutics Inc (KPTI.OQ)

KPTI.OQ on NASDAQ Stock Exchange Global Select Market

11.47USD
17 Nov 2017
Change (% chg)

$0.08 (+0.70%)
Prev Close
$11.39
Open
$11.31
Day's High
$11.54
Day's Low
$11.28
Volume
26,474
Avg. Vol
52,459
52-wk High
$14.63
52-wk Low
$7.54

Select another date:

Tue, Nov 7 2017

BRIEF-Point72 Asset Management L.P. reports 7.3 pct passive stake in Karyopharm Therapeutics Inc as of Nov. 3 - SEC filing‍​

* Point72 Asset Management L.P. reports 7.3 percent passive stake in Karyopharm Therapeutics Inc as of November 3, 2017 - SEC filing‍​ Source text: (http://bit.ly/2h9XeaC) Further company coverage:

BRIEF-Karyopharm Q3 loss per share $0.65

* Karyopharm reports third quarter 2017 financial results and highlights recent progress

BRIEF-Karyopharm and Ono Pharmaceutical sign exclusive license agreement to develop and commercialize Selinexor and KPT-8602 in Japan and other countries in Asia

* Karyopharm and Ono Pharmaceutical Co. Ltd. sign exclusive license agreement to develop and commercialize Selinexor and KPT-8602 in Japan and other countries in Asia

BRIEF-Karyopharm reports positive data from ongoing cancer drug study

* Karyopharm announces successful outcome from phase 2 portion of phase 2/3 seal study evaluating selinexor in patients with previously treated advanced dedifferentiated liposarcoma

BRIEF-Karyopharm appoints Michael Falvey as CFO, adds new clinical strategy

* Karyopharm appoints Michael Falvey as chief financial officer, adds new clinical strategy and human resources executives and reports inducement grant under NASDAQ listing rule 5635(c)(4)

BRIEF-Karyopharm presents selinexor, KPT-9274 clinical data

* Karyopharm announces presentation of selinexor and KPT-9274 clinical data at the European Society of Medical Oncology 2017 annual meeting

BRIEF-Karyopharm Therapeutics Q2 loss per share $0.64

* Karyopharm reports second quarter 2017 financial results and highlights recent progress

BRIEF-Karyopharm doses first patient in pivotal phase 3 boston study

* Karyopharm doses first patient in pivotal phase 3 boston study evaluating selinexor in patients with relapsed/refractory multiple myeloma

Select another date: